Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 9/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.43 |
| ▸ | RELA | Q04206 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9946094 | 0.83 | LPL (0.47) | MAOBFFAR1 | |
| SCHEMBL10784840 | 0.77 | LTA4H (0.64) | MAOBFFAR1FFAR4SMN1; SMN2RAB9A | |
| SCHEMBL16440937 | 0.77 | APP (0.56) | MAOBFFAR1 | |
| SCHEMBL22151428 | 0.75 | LMNA (0.58) | ENPP2MAOBTP53PKMNFKB1 | |
| SCHEMBL2555065 | 0.75 | ENPP2 (0.71) | ENPP2MAOBTP53PKMNFKB1 | |
| SCHEMBL3918100 | 0.74 | CYP4F2 (0.56) | MAOBFFAR1FFAR4TP53PKM | |
| SCHEMBL9946072 | 0.74 | ENPP2 (0.46) | ENPP2MAOBFFAR1TP53PKM | |
| SCHEMBL3920928 | 0.74 | MRGPRX4 (0.56) | MAOBFFAR1FFAR4TP53PKM | |
| SCHEMBL3762431 | 0.74 | SMPD1 (0.55) | MAOBTP53SMN1; SMN2 | |
| SCHEMBL9893590 | 0.73 | ENPP2 (1.00) | ENPP2MAOBFFAR1FFAR4AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | ENPP2 147/4885MAOB 780/4885FFAR1 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.